


Case MC058YP

In the Claims



1. Cancel.
2. Cancel.
3. Cancel.
4. Cancel.
5. Cancel.
6. Cancel.
7. Cancel.
8. Cancel.
9. Cancel.
10. Cancel.
11. Cancel.
12. Cancel.
13. Cancel.
14. Cancel.
15. Cancel.
16. Cancel.
17. A compound of structural formula I:



I

or a pharmaceutically acceptable salt, enantiomer, diastereomer, pro drug or mixture thereof, wherein

X is $(CH_2)_n$, O or S;

Y represents $(C(R^b)_2)_n$, triple bond,  or  ;

Case MC058YP

Ar₂ independently represent (CH₂)_mC₆₋₁₀aryl, (CH₂)_mC₅₋₁₀heteroaryl, (CH₂)_mC₃₋₁₀heterocycloalkyl, (CH₂)_mC₃₋₈cycloalkyl said cycloalkyl, heterocycloalkyl, aryl or heteroaryl unsubstituted or substituted with 1-3 groups of R_a;

R_a represents C₁₋₆alkoxy, C₁₋₆alkyl, CF₃, nitro, amino, cyano, C₁₋₆alkylamino, or halogen;

R^b independently represents H, halogen, C₁₋₆alkyl, C₃₋₆cylcoalkyl or

== represents a double or single bond;

n represents 0-4; and

m represents 0-8.

18. The compound according to claim 17 wherein X and Y are (CH₂)_n, == represents a double bond; and Ar₂ is phenyl.

19. The compound according to claim 18 wherein X is (CH₂)_n and n is 1 and Y is (CH₂)_n and n is 3.